Omeros (NASDAQ:OMER) Raised to Hold at StockNews.com

Omeros (NASDAQ:OMER) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

A number of other equities analysts have also issued reports on OMER. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price target on shares of Omeros in a research note on Tuesday, May 13th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Friday. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Stock Up 3.4%

OMER traded up $0.11 during trading on Monday, reaching $3.32. The stock had a trading volume of 2,093,206 shares, compared to its average volume of 654,615. The stock has a 50 day moving average of $7.06 and a two-hundred day moving average of $8.17. The firm has a market capitalization of $193.58 million, a price-to-earnings ratio of -1.44 and a beta of 2.42. Omeros has a 1-year low of $2.97 and a 1-year high of $13.60.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.05). On average, research analysts forecast that Omeros will post -3.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Omeros

A number of institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in Omeros during the fourth quarter worth about $124,000. Price T Rowe Associates Inc. MD raised its position in Omeros by 12.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 39,582 shares of the biopharmaceutical company’s stock worth $392,000 after purchasing an additional 4,401 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Omeros during the 4th quarter worth $46,000. Cerity Partners LLC grew its holdings in Omeros by 9.9% during the 4th quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company’s stock worth $286,000 after acquiring an additional 2,600 shares during the period. Finally, Franklin Resources Inc. acquired a new stake in Omeros during the 4th quarter worth $130,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.